Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma - Transplantation ...
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia
Daratumumab regimen extends PFS among certain patients with relapsed or refractory myeloma
Daratumumab Re-Treatment Patterns. DPd: daratumumab, pomalidomide, and... | Download Scientific Diagram
Daratumumab Alone or in Combination with Lenalidomide/Dexamethasone or Pomalidomide/Dexamethasone for Relapsed/Refractory MM | Research To Practice
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment | Leukemia
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
When and How to Treat Relapsed Multiple Myeloma | American Society of Clinical Oncology Educational Book
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma | NEJM
Phase Ib MMY1001: Daratumumab Plus Pom/Dex for Patients With R/R MM - ppt download
Subcutaneous daratumumab plus pomalidomide-dexamethasone: an effective treatment option for MM - BJH
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients - ScienceDirect
Newly Diagnosed: D + VTD Treatment | DARZALEX® IV (daratumumab)
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement - Justin R Arnall, Saad Z Usmani, Hawawu
Impressive Results With Daratumumab Plus Lenalidomide/Dexamethasone in Multiple Myeloma - The ASCO Post
Subcutaneous daratumumab plus pomalidomide and dexamethasone in R/R MM - Medical Conferences
Relapsed: D + PD Treatment | DARZALEX® IV (daratumumab)
Daratumumab - wikidoc
Suggested options for the treatment of relapsed multiple myeloma in... | Download Scientific Diagram
ASH 2020: Subcutaneous DARZALEX® Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma – OncoPrescribe
Omnihealth Practice | APOLLO: Phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
